In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Apothogen Inc.

Division of AstraZeneca PLC

Latest From Apothogen Inc.

Early-Stage Biopharma Investors Opt for Safer Bets in 2002

Discovery risk is for VCs like yesterday's newspaper. With the Big Pharma market for discovery tools abysmally quiet, early-stage funding for such firms saw a steep decline.
BioPharmaceutical Strategy

Deal Statistics Quarterly, Q4 2001

In Vivo presents another installment of our quarterly review of dealmaking--in this case October to Decemeber 2001. Our data come from Windhover's Strategic Transactions Database. We include medical device financings by deal type; diagnostic financings by industry segment; pharma and biotech alliances by therapeutic category and industry segment; pharma and biotech financings by market segment, and pharma and biotech M&A.
BioPharmaceutical Medical Device

The Impact of Bigness in the Life Sciences: A View from Windhover's Start-Up Symposium

Bigness is pervading the life sciences. Larger investments and larger partners are driving start-ups toward the largest markets to get ROI, encouraging in-licensing and rollup strategies. In devices, the trend towards size comes at the expense of developing niche markets. Meanwhile, biotechs are realizing they must integrate more and more technologies in parallel to get a complete biological picture of disease.
BioPharmaceutical Medical Device

Starting Big

Increasing fund size, a depressed but competitive public stock market, and rule-bound money managers unable to even consider investing in small firms are compelling private investors to seek new, deliberately big models for start-up firms. Some VCs are making long-term bets on star-powered teams of people trying to integrate brand-new technologies. If fully-formed start-ups can dramatically improve the drug discovery process, and retain the value they build, they stand to enjoy huge step-ups in valuation when they eventually do go public. Investors seeking faster-than-average returns think they can quickly build integrated-technology companies by buying the basic underpinnings at discount-for instance, by acquiring experienced research groups from major drugmakers anxious to cut costs-then quickly taking the start-ups public. In-licensing may also offer a faster route to ROI. Investors are updating the old model, applying stacks of cash to help certain start-ups acquire operating infrastructure, and reach for big opportunities. Backers expect that big-name founders will be able to net products that elude less experienced people.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • AstraZeneca PLC
  • Senior Management
  • Ernest Mario, PhD, Chmn.
  • Contact Info
  • Apothogen Inc.
    Phone: (910) 251-0081
    c/o PPD Inc.
    3151 S. 17th St
    Wilmington, NC 28412